Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies to address significant market opportunities, primarily in ophthalmic conditions. Our lead product candidate, TP-03, is a novel therapeutic currently in Phase 2b/3 clinical trials for the treatment of Demodex blepharitis, showcasing our commitment to addressing unmet medical needs. As a company of 101-250 employees, we leverage a robust tech stack including DNSSEC, Amazon Web Services (AWS) for cloud infrastructure, and BootstrapCDN for content delivery, ensuring a mobile-optimized experience for our users. We operate in a hybrid work environment and offer remote work options for many roles. Our culture thrives on commitment to patients, empowering innovation, and teamwork to amplify impact. We are a publicly traded company (NASDAQ:TARS), and our Series B funding round helped us to accelerate our research and development efforts. Our team is passionate about our mission to create category-creating products and is empowered to champion innovation. We have built a team of experts in ophthalmology and other therapeutic categories, with a focus on delivering on our promise to patients. Tarsus Pharmaceuticals is dedicated to attracting and retaining top talent by providing competitive compensation, including a comprehensive benefits package, stock equity and ensuring work-life balance through generous paid time off.